Former postdoctoral fellow Michael McAlpine's recent paper in the Journal of the American Chemical Society was highlighted in a writeup in Nature Chemistry.  Mike will begin at Princeton University as an Assistant Professor in September. 

The Grand Duchy of Luxembourg has announced an ambitious plan to increase the pace of innovation in the areas of molecular biology, systems biology, and personalized medicine.   To achieve this goal, Luxembourg is investing $200M in three collaborations, one of which is headed by NSBCC co-director Leroy Hood. 

In a Watson lecture on May 14, Mark Davis, NSBCC investigator and Caltech's Schlinger Professor of Chemical Engineering.  Davis, also a member of the experimental therapeutics program at the City of Hope's Comprehensive Cancer Center, explained how nanoparticle medicines, or nanomedicines, have the potential to change the way cancer is treated.

Hamilton Jordan, good friend and NSBCC External Advisory Board Member, died in his home of cancer on Tuesday, May 20, 2008.

NanoSystems Biology Cancer Center (NSBCC) Director Jim Heath testified April 24 2008, before the Senate Subcommittee on Science, Technology and Innovation, on the need for continued funding for the national Nanotechnology Initiative. 

Mark Davis, NSBCC Principal Investigator and Warren and Katharine Schlinger Professor of Chemical Engineering at Caltech, has launched a promising phase II clinical trial for patients with ovarian cancer. 

Professor Jim Heath, NSBCC Director and Elizabether W. Gilloon Professor & Professor of Chemistry at the California Institute of Technology and colleagues have received approval to test a device designed to detect proteins in human blood that might signal a variety of diseases, including cancer, from a single finger-prick of blood. 

Akram Boukai wins MSR Gold Award!!

Leroy Hood, MD, PhD, Co-director of the NSBCC and President of the Institute for Systems Biology in Seattle, Washington, was selected as winner of the Pittcon Heritage Award, which is jointly sponsored by the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon) and the Chemical Heritage Foundation.

Dr. Paul Mischel, NSBCC Principal Investigator and professor of pathology and pharmacology and a researcher at UCLA's Jonsson Cancer Center, commented January 14, 2008 in the Los Angeles Times about brain cancer vaccines.